DPPIV (CD26) as a novel stem cell marker in Ph plus chronic
myeloid leukaemia

J 2014

DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia

VALENT, Peter, Irina SADOVNIK, Zdeněk RÁČIL, Harald HERRMANN, Katharina BLATT et. al.

Basic information

Original name

DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia

Authors

VALENT, Peter (40 Austria), Irina SADOVNIK (40 Austria), Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution), Harald HERRMANN (40 Austria), Katharina BLATT (40 Austria), Sabine CERNY-REITERER (40 Austria), Gregor EISENWORT (40 Austria), Thomas LION (40 Austria), Tessa HOLYOAKE (826 United Kingdom of Great Britain and Northern Ireland) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

European Journal of Clinical Investigation, HOBOKEN, WILEY-BLACKWELL, 2014, 0014-2972

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.734

RIV identification code

RIV/00216224:14110/14:00078413

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/eci.12368

UT WoS

000345759100012

Keywords in English

Diagnostics; leukaemia; leukaemic stem cells; stem cell; phenotyping

Abstract

V originále

The concept of leukaemic stem cells (LSCs) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients. Some of the newly discovered LSC markers seem to be expressed in a disease-specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia (CML) appears to be CD26, also known as dipeptidylpeptidase IV. Expression of CD26 is largely restricted to CD34(+)/CD38(-) LSCs in BCR/ABL1(+) CML, but is not found on LSCs in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML, BCR/ABL1(p210)+ acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD26 usually is not expressed on normal bone marrow (BM) stem cells. Functionally, CD26 is a cytokine-targeting surface enzyme that may facilitate the mobilization of LSCs from the BM niche. In this article, we review our current knowledge about the biology and function of CD26 on CML LSCs and discuss the diagnostic potential of this new LSC marker in clinical haematology.

Citovat

VALENT, Peter, Irina SADOVNIK, Zdeněk RÁČIL, Harald HERRMANN, Katharina BLATT, Sabine CERNY-REITERER, Gregor EISENWORT, Thomas LION, Tessa HOLYOAKE and Jiří MAYER. DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia. European Journal of Clinical Investigation. HOBOKEN: WILEY-BLACKWELL, 2014, vol. 44, No 12, p. 1239-1245. ISSN 0014-2972. Available from: https://dx.doi.org/10.1111/eci.12368.

@article{1216811,
   author = {Valent, Peter and Sadovnik, Irina and Ráčil, Zdeněk and Herrmann, Harald and Blatt, Katharina and CernyandReiterer, Sabine and Eisenwort, Gregor and Lion, Thomas and Holyoake, Tessa and Mayer, Jiří},
   article_location = {HOBOKEN},
   article_number = {12},
   doi = {http://dx.doi.org/10.1111/eci.12368},
   keywords = {Diagnostics; leukaemia; leukaemic stem cells; stem cell; phenotyping},
   language = {eng},
   issn = {0014-2972},
   journal = {European Journal of Clinical Investigation},
   title = {DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia},
   volume = {44},
   year = {2014}
}

TY  - JOUR
ID  - 1216811
AU  - Valent, Peter - Sadovnik, Irina - Ráčil, Zdeněk - Herrmann, Harald - Blatt, Katharina - Cerny-Reiterer, Sabine - Eisenwort, Gregor - Lion, Thomas - Holyoake, Tessa - Mayer, Jiří
PY  - 2014
TI  - DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia
JF  - European Journal of Clinical Investigation
VL  - 44
IS  - 12
SP  - 1239-1245
EP  - 1239-1245
PB  - WILEY-BLACKWELL
SN  - 00142972
KW  - Diagnostics
KW  - leukaemia
KW  - leukaemic stem cells
KW  - stem cell
KW  - phenotyping
N2  - The concept of leukaemic stem cells (LSCs) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients. Some of the newly discovered LSC markers seem to be expressed in a disease-specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia (CML) appears to be CD26, also known as dipeptidylpeptidase IV. Expression of CD26 is largely restricted to CD34(+)/CD38(-) LSCs in BCR/ABL1(+) CML, but is not found on LSCs in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML, BCR/ABL1(p210)+ acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD26 usually is not expressed on normal bone marrow (BM) stem cells. Functionally, CD26 is a cytokine-targeting surface enzyme that may facilitate the mobilization of LSCs from the BM niche. In this article, we review our current knowledge about the biology and function of CD26 on CML LSCs and discuss the diagnostic potential of this new LSC marker in clinical haematology.
ER  -

VALENT, Peter, Irina SADOVNIK, Zdeněk RÁČIL, Harald HERRMANN, Katharina BLATT, Sabine CERNY-REITERER, Gregor EISENWORT, Thomas LION, Tessa HOLYOAKE and Jiří MAYER. DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia. \textit{European Journal of Clinical Investigation}. HOBOKEN: WILEY-BLACKWELL, 2014, vol.~44, No~12, p.~1239-1245. ISSN~0014-2972. Available from: https://dx.doi.org/10.1111/eci.12368.

Detailed Information on Publication Record